12:07 Monday 18th February 2002
GW Pharmaceuticals PLC, developer of a portfolio of non-smoked cannabis-based prescription medicines, said it welcomes the government's announcement that it will ask the National Institute for Clinical Excellence (NICE) to examine the possible provision of the company's medicines by the National Health Service.
GW Pharmaceutical said it is currently conducting Phase III clinical trials of cannabis-based medicines for the treatment of Multiple Sclerosis, cancer pain and other forms of nerve pain, with the aim of preparing data for Product Licence Approval.
The company expects to bring its first prescription medicines to market in early 2004.
The cannabis-based medicines are being administered by means of a sublingual (under-the-tongue) spray, it said.
In the event of a licence being granted,
the Home Secretary has already indicated that the Misuse of Drugs Act 1971
will be amended to allow the prescribing of cannabis-based medicines, the
Copyright © 2002 Ananova Ltd